HomeHealthcareDrug PipelineUnited Kingdom Anti-Rheumatic Drug Market

United Kingdom Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2022-2027)

Industry insights into anti-rheumatic drug development, precision medicine approaches, and patient care trends in the United Kingdom.

📥 Download Free Sample💬 Speak to Analyst
Avail 25% Off on Checkout
$2,850
Single User License
Access Full Insights
Market Size
USD 5.66 billion
by 2027
CAGR
3.93%
2020-2027
Base Year
2019
Forecast Period
2020-2027
Projection
Report OverviewSegmentationTable of ContentsCustomize Report

Report Overview

The United Kingdom’s antirheumatic drug market was valued at US$4.33 billion in 2020. The market is projected to grow at a CAGR of 3.93% to attain a value of US$5.66 billion by 2027.

The market in the United Kingdom is projected to show nominal growth over the next five years on account of the high prevalence of rheumatic diseases in the country coupled with the presence of a world-class healthcare sector in the country. According to the United Kingdom’s National Health Service, more than 10 million people in the country suffer from arthritis and numerous other conditions. This, in turn, is anticipated to significantly drive the demand for various types of anti-rheumatic drugs and thus positively impact the market growth in the country in the coming years. Furthermore, the growing healthcare expenditure further enables the citizens to avail of costly treatments and medicines, which is also projected to positively impact the market growth in the United Kingdom throughout the forecast period.

Additionally, with the growing number of geriatric people, aged 65 years and above in the United Kingdom, the number of age-associated diseases such as joint pain, back pain, and rheumatoid arthritis, among others, will also continue to soar, hence the market for various types of antirheumatic drugs will also soar due to their requirement for disease treatment. According to the World Bank estimates, the geriatric population (65 years of age or older) in the United Kingdom has grown from a population size of 11.706 million in 2015 to a population size of 12.231 million in 2018.

The United Kingdom’s antirheumatic drug market has been segmented on the basis of the type of disease, type of molecule, and sales channel. Type of disease, the market has been classified on the basis of osteoarthritis, rheumatoid arthritis, gout, lupus, and others. The market has been segmented based on molecule type; the market has been segmented based on pharmaceuticals and biopharmaceuticals.  By the sales channel, the segmentation has been done on the basis of prescription and over-the-counter (OTC).

United Kingdom Anti-Rheumatic Drug Market Scope:

Report Metric Details
Total Market Size in 2020 USD 4.33 billion
Total Market Size in 2027 USD 5.66 billion
Forecast Unit Billion
Growth Rate 3.93%
Study Period 2015 to 2027
Historical Data 2015 to 2018
Base Year 2019
Forecast Period 2020 – 2027
Segmentation Type of Disease, Drug Class, Sales Channel
Companies
  • AbbVie Inc.
  • Amget Inc.
  • Johnson and Johnson
  • Pfizer Inc.
  • GlaxoSmithKline plc

REPORT DETAILS

Report ID:KSI061613639
Published:Jul 2022
Pages:90
Format:PDF, Excel, PPT, Dashboard
📥 Download Sample📞 Speak to Analyst📧 Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us

Frequently Asked Questions

The United Kingdom's anti-rheumatic drug market was valued at US$4.33 billion in 2020. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.93%, reaching an estimated value of US$5.66 billion by 2027.

The market's growth is primarily driven by the high prevalence of rheumatic diseases, with over 10 million people in the UK suffering from arthritis and related conditions. Additionally, a world-class healthcare sector, growing healthcare expenditure enabling access to costly treatments, and an increasing geriatric population contribute significantly to market expansion.

The report segments the market based on the type of disease, including Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, and others. Further segmentation covers molecule types such as pharmaceuticals and biopharmaceuticals, and sales channels, distinguishing between prescription and over-the-counter (OTC) drugs.

The COVID-19 pandemic initially had a negative impact on the UK anti-rheumatic drug market. However, certain DMARDs and biologics routinely used for rheumatoid arthritis, such as hydroxychloroquine, sarilumab, tocilizumab, and anakinra, were studied as potential COVID-19 treatments, which subsequently boosted growth prospects for manufacturers of these specific medications during the anticipated period.

The growing number of people aged 65 and above in the United Kingdom directly correlates with a rise in age-associated conditions like joint pain, back pain, and rheumatoid arthritis. This demographic shift necessitates increased demand for various anti-rheumatic drugs for disease treatment, thereby significantly driving market growth.

The report provides insights into key growth opportunities stemming from the high prevalence of rheumatic diseases and the robust healthcare infrastructure. It highlights the strategic importance of growing healthcare expenditure and demographic shifts, such as the increasing geriatric population, in shaping future market demand and potential for drug innovation across different molecule types and sales channels.

Related Reports

Healthcare

Veterinary API Market Size, Share, Opportunities, And Trends By Product Type (Antiparasitic, Anti-infectives, Vaccines, NSAIDs, Others), By Service Type (In House, Contract Outsourcing, Contract Development, Contract Manufacturing), By Synthesis Type (OMICS Chemical-Based API, Biological API, Highly Potent API (HPAPI)), By Route of administration (Oral, Injectable, Topical, Others), And By Geography - Forecasts From 2024 To 2029

Jun 2024
Healthcare

Atherosclerosis Drugs Market Size, Share, Opportunities, And Trends By Drug Class (Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta Blockers, Others), By Route of Administration (Injectable, Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), And By Geography - Forecasts From 2024 To 2029

Mar 2024
Healthcare

Preparative Chromatography Market Size, Share, Opportunities, And Trends By Product (Systems, Resins, Detectors, Consumables, Columns), By Application (Pharmaceuticals, Cosmetics, Food Ingredients, Molecular Biology and Diagnostics, Fine Chemical and Synthetic Chemistry, Environmental Chemistry, Forensic Sciences, Drugs of Abuse and Sports Drug Testing, Others), By End-user (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Food and Beverage Industry, Chemical Industry, Diagnostic Laboratories, Reference Laboratories, National Anti-doping Organizations, Academic and Research Institutes), And By Geography - Forecasts From 2024 To 2029

Mar 2024
Healthcare

PCSK9 Inhibitor Market Size, Share, Opportunities, And Trends By Drug Type (Repatha (Evolocumab), Praluent (Alirocumab), Bococizuma, Others), By Modality (Fully humanized monoclonal antibodies, siRNA), By Application (Clinical Application, Drug Development, Other), And By Geography - Forecasts From 2024 To 2029

Mar 2024
View All Reports